May 12, 2023
Bulletin interne de l'Institut Pasteur
Lassa fever: promising results for a vaccine candidate in a Phase I clinical trial
The Lassa arenavirus causes hemorrhagic fever and is a major problem in many West African countries, claiming 5,000 to 6,000 lives every year. There is therefore an urgent need to develop treatments and prepare for potential outbreaks. An international study involving Institut Pasteur researchers has reported the results of Phase I clinical trial for a Lassa fever vaccine.